Sorafenib in Advanced Hepatocellular Carcinoma

200812,841 citationsJournal Articlebronze Open Access

Authors

Josep M. Llovet · Universitat de Barcelona

Sergio Ricci · University of Pisa

Vincenzo Mazzaferro · Fondazione IRCCS Istituto Nazionale dei Tumori

Philip Hilgard · University of Duisburg-Essen

Edward Gane · Auckland City Hospital

Jean Frédéric Blanc · Hôpital Saint-André

André Cosme de Oliveira

Abstract

In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo. (ClinicalTrials.gov number, NCT00105443.)

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Liver physiology and pathology Cancer Mechanisms and Therapy

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 359, Issue 4, pp. 378-390

DOI: 10.1056/nejmoa0708857

Field-Weighted Citation Impact: 240.76